Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05762471 · ClinicalTrials.gov registry record · Phase 1
Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
A Phase 1 study, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 142
- Enrollment target
NCT05762471 is a Phase 1 study that has completed, run by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. The registered enrollment target is 142 participants.
The verdict
NCT05762471, a Phase 1 study, has completed, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 142 participants
- Enrollment target
Study Summary
This study will evaluate safety, tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) effects on GSBR-1290 in healthy overweight/obese volunteers (HOV) and Type 2 Diabetes Mellitus on Metformin (T2DM) This study includes 5 planned cohorts. Participants will receive multiple-ascending doses of GSBR-1290 or Placebo from Day 1 to Day 84
Interventions
- DRUG Placebo
- DRUG GSBR-1290
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2023-01-09 |
| Est. Completion | 2024-04-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05762471
The ClinicalTrials.gov registry entry for NCT05762471 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05762471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05762471 about?
NCT05762471 is a clinical study titled "Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus". This study will evaluate safety, tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) effects on GSBR-1290 in healthy overweight/obese volunteers (HOV) and Type 2 Diabetes Mellitus on Metformin (T2DM) This study includes 5 planned cohorts. Participants will receive multiple-ascending...
What is the current status of trial NCT05762471?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 142 participants. The study started on 2023-01-09. Estimated completion is 2024-04-11.
What interventions are being tested in trial NCT05762471?
The interventions under investigation include: Placebo (DRUG), GSBR-1290 (DRUG).
Who is sponsoring clinical trial NCT05762471?
This trial is sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.